What is Saranas?
Saranas operates at the intersection of medical technology and patient safety, specializing in the development of diagnostic tools designed to detect internal bleeding complications in real-time. The company's flagship product, the Early Bird Bleed Monitoring System, provides physicians with actionable data during vascular access procedures, allowing for immediate intervention. This capability is essential for mitigating downstream clinical consequences, thereby optimizing healthcare delivery and reducing the economic burden associated with post-procedural complications. As a privately held entity, Saranas has demonstrated a consistent trajectory of growth, moving from early-stage development to a more mature phase of market penetration and clinical adoption.
How much funding has Saranas raised?
Saranas has raised a total of $28.1M across 7 funding rounds:
Angel/Seed
$1.2M
Unspecified
$2.4M
Series A
$3.5M
Private Equity
$1.4M
Series B
$4M
Series C
$2.8M
Series B
$12.8M
Angel/Seed (2014): $1.2M, investors not publicly disclosed
Unspecified (2015): $2.4M, investors not publicly disclosed
Series A (2016): $3.5M supported by Houston Angel Network
Private Equity (2016): $1.4M, investors not publicly disclosed
Series B (2017): $4M, investors not publicly disclosed
Series C (2018): $2.8M, investors not publicly disclosed
Series B (2021): $12.8M led by Baird Capital and S3 Ventures
Key Investors in Saranas
Baird Capital
Baird Capital is a global private equity and venture capital firm that partners with founder-led B2B tech and healthcare services companies to provide operational support and scale.
S3 Ventures
S3 Ventures is the largest venture capital firm focused on Texas, specializing in healthcare technology and business software with a patient, flexible investment approach.
Houston Angel Network
The Houston Angel Network is a prominent group of accredited investors providing early-stage capital and mentorship to high-growth startups within the Texas innovation ecosystem.
What's next for Saranas?
With the recent influx of capital, Saranas is well-positioned to scale its operational footprint and expand the clinical utility of its monitoring platform. The strategic focus will likely shift toward broader market adoption and the integration of its technology into standard vascular access protocols across major healthcare systems. By leveraging the expertise of its institutional backers, the company aims to solidify its market position as a leader in bleeding complication mitigation. Future milestones will likely involve scaling manufacturing capabilities and pursuing additional regulatory clearances to broaden the application of its proprietary sensor technology, ultimately aiming to set a new standard of care in interventional medicine.
See full Saranas company page
